Syntara: Half Year Report and Appendix 4D
Filed with ASX · · 24 pages · English
There were no dividends paid, recommended or declared during the current financial period. Comments The loss for the Company after providing for income tax amounted to $5,859,000 (31 December 2024: $2,716,000). 3. Net tangible assets 4. Control gained over entities Not applicable. 5. Loss of control over entities Not applicable. 6. Dividends Current period There were no dividends paid, recommended
Story so far
Earlier from Syntara
- Quarterly Activities/Appendix 4C Cash Flow Report
- Amsulostat and Garvan in MRFF funded pancreatic trial
- SNT-4728 Phase 2 iRBD Parkinsons UK Trial fully recruited
- Skin scarring program to progress on positive Phase1a result
- Quarterly Shareholder Report and Appendix 4C
Later from Syntara
- Positive FDA feedback for Amsulostat P2b trial
- Continuation of trading halt
- $8m placement and share purchase plan
- Share Purchase Plan Offer Booklet
- Results of Share Purchase Plan
Follow Syntara into a list and get an email when it puts out news.
Follow Syntara